Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis

Company Overview

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing small-molecule therapies for cancer and other serious diseases. The company’s research is centered on restoring programmed cell death, or apoptosis, by targeting proteins that help cancer cells survive, including members of the BCL-2 family, inhibitor of apoptosis proteins and the MDM2-p53 pathway.

Its investigational portfolio includes lisaftoclax (APG-2575), a BCL-2 inhibitor being studied in hematologic malignancies, and alrizomadlin (APG-115), an MDM2-p53 inhibitor being evaluated in oncology programs. Ascentage also has additional preclinical and clinical-stage candidates targeting apoptosis-related mechanisms and other disease pathways.

Founded in 2012, Ascentage conducts research and clinical development activities in China and internationally, with programs designed for potential use across multiple cancer types. The company is led by Dr. Dajun Yang, its co-founder, chairman and chief executive officer. Ascentage Pharma is listed on the Hong Kong Stock Exchange under the symbol 6855, while its securities also trade over the counter in the United States under the symbol ASPHF.

Key Stats

• Today's Range: $3.75 to $3.75
• 50-Day Range: $3.75 to $4.53
• 52-Week Range: $3.75 to $5.05
• Volume: N/A
• Average Volume: 1,129 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ASPHF
• CIK: N/A
• Web: www.ascentage.cn
• Phone: 86-512-8555-7777
• Fax: N/A
• Employees: 767
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A